 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
3-14-2024
Insider Buy |
Jason Lettmann
CHIEF EXECUTIVE OFFICER |
$11.31
CAGR »
|
$49,771.48
4,400 shares |
12-14-2020
Insider Buy |
G. Walmsley Graham
Director |
$76.00
CAGR »
|
$1,520,000.00
20,000 shares |
7-21-2020
Insider Buy |
LSV Associates, LLC
>10% Owner |
$19.00
CAGR »
|
$7,600,000.00
400,000 shares |
7-21-2020
Insider Buy |
Robert J. Adelman
|
$19.00
CAGR »
|
$16,207,000.00
853,000 shares |
7-21-2020
Insider Buy |
Jason Lettmann
Director and >10% Owner |
$19.00
CAGR »
|
$7,600,000.00
400,000 shares |
7-21-2020
Insider Buy |
Vivo Capital IX, LLC
>10% Owner |
$19.00
CAGR »
|
$18,525,000.00
975,000 shares |
7-21-2020
Insider Buy |
Peter S. Garcia
Chief Financial Officer |
$19.00
CAGR »
|
$57,000.00
3,000 shares |
7-21-2020
Insider Buy |
Steffen Pietzke
VP Fin & Chief Acct Officer |
$19.00
CAGR »
|
$57,000.00
3,000 shares |
7-21-2020
Insider Buy |
Corey S. Goodman
Director and >10% Owner |
$19.00
CAGR »
|
$16,150,000.00
850,000 shares |
7-21-2020
Insider Buy |
Rekha Hemrajani
Director |
$19.00
CAGR »
|
$57,000.00
3,000 shares |
7-21-2020
Insider Buy |
G. Walmsley Graham
Director |
$19.00
CAGR »
|
$18,525,000.00
975,000 shares |
Also See: Institutional Holders of ALXO
Also See: SEC filings
Below we present the annualized performance delivered by ALX Oncology Holdings stock since 3-14-2024 (the date of the most recent
insider purchase). The performance of the investment from the time ALX Oncology Holdings insider buying occurred is the ultimate
test of whether insiders were right about ALXO being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/15/2024 |
|
| End date: |
04/22/2024 |
|
| Start price/share: |
$11.30 |
|
| End price/share: |
$14.23 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
25.93% |
|
| Annualized Gain: |
249.06% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$12,593.00 |
|
| Years: |
0.10 |
|
ALX Oncology Holdings Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent ALX Oncology Holdings insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding ALXO
|
|
Free ALXO Email Alerts:
